Shinagawa H, Yamaga H, Houchigai H, Sumita Y, Sunagawa M
Sumitomo Pharmaceuticals Research Center, Osaka, Japan.
Bioorg Med Chem. 1997 Mar;5(3):601-21. doi: 10.1016/s0968-0896(96)00273-8.
A series of 1 beta-methylcarbapenems containing variously C-2 substituted thiazol-2-ylthio groups were synthesized, and their in vitro anti-MRSA activity was examined. Among them, 1 beta-methyl-2-(4-arylthiazol-2-ylthio)carbapenems exhibited superior anti-MRSA activity. Introduction of a cationic moiety in the C-2 side chain not only reduced the binding to HSA but also increased the stability against DHP-I, without affecting the anti-MRSA activity. It was also found that the distance between the cationic moiety and the carbapenem skeleton was related to the strength of HSA binding and the stability against DHP-I.